FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR Status
August 16, 2022

Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.

Pretreatment Neutrophil-to-Lymphocyte Ratio Linked to OS in Endometrial Cancer
August 16, 2022

Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.

Sacituzumab Govitecan Yields Significant OS Improvement Vs Physician’s Choice in HR+/HER2– Metastatic Breast Cancer
August 16, 2022

Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s choice of treatment.

The High Cost of Oral Anticancer Drugs: What Does the Future Hold?
August 16, 2022

ONCOLOGY Co-Editor-in-Chief Julie M. Vose, MD, MBA, explores high drug costs and financial toxicity.

Armamentarium for Graft vs Host Disease Prophylaxis
August 16, 2022

Hematologist/oncologists provide a broad overview of the pharmacologic agents used to prevent graft vs host disease at their institutions.

GVHD in the Context of Stem Cell or Allogeneic Transplant
August 16, 2022

Expert panelists elucidate the occurrence of graft vs host disease in patients receiving either stem cell or allogeneic transplantation.

Tanio S. Bekaii-Saab, MD, on Panitumumab/FOLFOX as Standard for Left-Sided, RAS Wild-Type CRC From the PARADIGM Trial
August 15, 2022

Data from the PARADIGM trial that were presented at 2022 ASCO demonstrated that panitumumab plus FOLFOX should be standard of care for patients with left-sided, RAS wild-type colorectal cancer, according to Tanio S. Bekaii-Saab, MD.

Venetoclax Schedule Modifications Linked to Longer OS in Real-World Newly Diagnosed AML
August 15, 2022

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

Significant Improvement in PFS Observed With T-DXd Vs Physician’s Choice of Therapy in HER2+ Advanced Breast Cancer
August 15, 2022

The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.

Pembrolizumab Plus Lenvatinib Confers Promising Efficacy in Malignant Pleural Mesothelioma
August 15, 2022

Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.